Cargando…

Down-Regulated FOXO1 in Refractory/Relapse Childhood B-Cell Acute Lymphoblastic Leukemia

Background: Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, with an overall prevalence of 4/100,000, accounting for 25–30% of all childhood cancers. With advances in childhood ALL treatment, the cure rate for childhood ALL has exceeded 80% in most countries. However, refracto...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Qingqing, Jiang, Chuang, Liu, Haiyan, Hao, Wenge, Wang, Pengfei, Huang, Haiying, Li, Ziping, Qian, Jiabi, Qian, Maoxiang, Zhang, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686545/
https://www.ncbi.nlm.nih.gov/pubmed/33262946
http://dx.doi.org/10.3389/fonc.2020.579673
_version_ 1783613348561027072
author Zheng, Qingqing
Jiang, Chuang
Liu, Haiyan
Hao, Wenge
Wang, Pengfei
Huang, Haiying
Li, Ziping
Qian, Jiabi
Qian, Maoxiang
Zhang, Hui
author_facet Zheng, Qingqing
Jiang, Chuang
Liu, Haiyan
Hao, Wenge
Wang, Pengfei
Huang, Haiying
Li, Ziping
Qian, Jiabi
Qian, Maoxiang
Zhang, Hui
author_sort Zheng, Qingqing
collection PubMed
description Background: Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, with an overall prevalence of 4/100,000, accounting for 25–30% of all childhood cancers. With advances in childhood ALL treatment, the cure rate for childhood ALL has exceeded 80% in most countries. However, refractory/relapsed ALL remains a leading cause of treatment failure and subsequent death. Forkhead box O1 (FOXO1) belongs to the forkhead family of transcription factors, but its role in B-cell ALL (B-ALL) has not been determined yet. Procedures: RNA sequencing was applied to an ALL case with induction failure (IF) to identify the possible genetic events. A cytokine-dependent growth assay in Ba/F3 cells was used to test the leukemic transformation capacity of MEIS1–FOXO1. The propidium iodide (PI) staining method was used to evaluate the effect of MEIS1–FOXO1 on cycle distribution. FOXO1 transactivity was examined using a luciferase reporter assay. FOXO1 mRNA expression levels were examined using real-time quantitative PCR among 40 children with B-ALL treated with the CCCG-ALL-2015 protocol. Association analysis was performed to test the correlation of FOXO1 transcription with childhood B-ALL prognosis and relapse in a series of GEO datasets. An MTT assay was performed to test the drug sensitivity. Results: In this ALL case with IF, we identified a novel MEIS1–FOXO1 fusion gene. The transactivity of MEIS1–FOXO1 was significantly lower than that of wild-type FOXO1. MEIS1–FOXO1 potentiated leukemia transformation and promoted Ba/F3 cell cycle S-phase entry. Low FOXO1 transcription levels were found to be strongly associated with unfavorable ALL subtype, minimal residual disease (MRD) positivity, and relapse. Lower FOXO1 expression was associated with prednisone and cyclophosphamide resistance. Conclusions: Low FOXO1 transcription was associated with high-risk stratification and relapse in children with B-ALL, probably due to multi-drug resistance.
format Online
Article
Text
id pubmed-7686545
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-76865452020-11-30 Down-Regulated FOXO1 in Refractory/Relapse Childhood B-Cell Acute Lymphoblastic Leukemia Zheng, Qingqing Jiang, Chuang Liu, Haiyan Hao, Wenge Wang, Pengfei Huang, Haiying Li, Ziping Qian, Jiabi Qian, Maoxiang Zhang, Hui Front Oncol Oncology Background: Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, with an overall prevalence of 4/100,000, accounting for 25–30% of all childhood cancers. With advances in childhood ALL treatment, the cure rate for childhood ALL has exceeded 80% in most countries. However, refractory/relapsed ALL remains a leading cause of treatment failure and subsequent death. Forkhead box O1 (FOXO1) belongs to the forkhead family of transcription factors, but its role in B-cell ALL (B-ALL) has not been determined yet. Procedures: RNA sequencing was applied to an ALL case with induction failure (IF) to identify the possible genetic events. A cytokine-dependent growth assay in Ba/F3 cells was used to test the leukemic transformation capacity of MEIS1–FOXO1. The propidium iodide (PI) staining method was used to evaluate the effect of MEIS1–FOXO1 on cycle distribution. FOXO1 transactivity was examined using a luciferase reporter assay. FOXO1 mRNA expression levels were examined using real-time quantitative PCR among 40 children with B-ALL treated with the CCCG-ALL-2015 protocol. Association analysis was performed to test the correlation of FOXO1 transcription with childhood B-ALL prognosis and relapse in a series of GEO datasets. An MTT assay was performed to test the drug sensitivity. Results: In this ALL case with IF, we identified a novel MEIS1–FOXO1 fusion gene. The transactivity of MEIS1–FOXO1 was significantly lower than that of wild-type FOXO1. MEIS1–FOXO1 potentiated leukemia transformation and promoted Ba/F3 cell cycle S-phase entry. Low FOXO1 transcription levels were found to be strongly associated with unfavorable ALL subtype, minimal residual disease (MRD) positivity, and relapse. Lower FOXO1 expression was associated with prednisone and cyclophosphamide resistance. Conclusions: Low FOXO1 transcription was associated with high-risk stratification and relapse in children with B-ALL, probably due to multi-drug resistance. Frontiers Media S.A. 2020-11-11 /pmc/articles/PMC7686545/ /pubmed/33262946 http://dx.doi.org/10.3389/fonc.2020.579673 Text en Copyright © 2020 Zheng, Jiang, Liu, Hao, Wang, Huang, Li, Qian, Qian and Zhang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zheng, Qingqing
Jiang, Chuang
Liu, Haiyan
Hao, Wenge
Wang, Pengfei
Huang, Haiying
Li, Ziping
Qian, Jiabi
Qian, Maoxiang
Zhang, Hui
Down-Regulated FOXO1 in Refractory/Relapse Childhood B-Cell Acute Lymphoblastic Leukemia
title Down-Regulated FOXO1 in Refractory/Relapse Childhood B-Cell Acute Lymphoblastic Leukemia
title_full Down-Regulated FOXO1 in Refractory/Relapse Childhood B-Cell Acute Lymphoblastic Leukemia
title_fullStr Down-Regulated FOXO1 in Refractory/Relapse Childhood B-Cell Acute Lymphoblastic Leukemia
title_full_unstemmed Down-Regulated FOXO1 in Refractory/Relapse Childhood B-Cell Acute Lymphoblastic Leukemia
title_short Down-Regulated FOXO1 in Refractory/Relapse Childhood B-Cell Acute Lymphoblastic Leukemia
title_sort down-regulated foxo1 in refractory/relapse childhood b-cell acute lymphoblastic leukemia
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686545/
https://www.ncbi.nlm.nih.gov/pubmed/33262946
http://dx.doi.org/10.3389/fonc.2020.579673
work_keys_str_mv AT zhengqingqing downregulatedfoxo1inrefractoryrelapsechildhoodbcellacutelymphoblasticleukemia
AT jiangchuang downregulatedfoxo1inrefractoryrelapsechildhoodbcellacutelymphoblasticleukemia
AT liuhaiyan downregulatedfoxo1inrefractoryrelapsechildhoodbcellacutelymphoblasticleukemia
AT haowenge downregulatedfoxo1inrefractoryrelapsechildhoodbcellacutelymphoblasticleukemia
AT wangpengfei downregulatedfoxo1inrefractoryrelapsechildhoodbcellacutelymphoblasticleukemia
AT huanghaiying downregulatedfoxo1inrefractoryrelapsechildhoodbcellacutelymphoblasticleukemia
AT liziping downregulatedfoxo1inrefractoryrelapsechildhoodbcellacutelymphoblasticleukemia
AT qianjiabi downregulatedfoxo1inrefractoryrelapsechildhoodbcellacutelymphoblasticleukemia
AT qianmaoxiang downregulatedfoxo1inrefractoryrelapsechildhoodbcellacutelymphoblasticleukemia
AT zhanghui downregulatedfoxo1inrefractoryrelapsechildhoodbcellacutelymphoblasticleukemia